Orchid has developed the world's first whole genome sequencing for embryo screenings. We are able to read >99% of an embryo's DNA. This enables us to screen embryos for over 1200 known genetic causes of neurodevelopmental disorders, hereditary cancers, and birth defects, as well as provide traditional PGT-A and PGT-M testing, in one single screen. We are proud to help patients and providers make embryo selection choices that maximize chances of a successful pregnancy and healthy baby.